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The two operations most commonly used to treat displaced intracapsular hip fractures are total hip 
replacement (THR) and hemiarthroplasty. THR is a more complex procedure, takes longer, and is at 
higher risk of subsequent dislocation1. However, some small randomised controlled trials have 
reported better functional outcomes, fewer wound complications, and less need for secondary 
procedures after THR1,2. National guidelines therefore recommend offering THR to the fittest patients 
who are most likely to tolerate a bigger operation and also to benefit from better functional 
outcomes3,4. However, these recommendations have not been universally implemented. An 
international survey of orthopaedic surgeons found that 73% prefer hemiarthroplasty5 and there is 
evidence of widespread variation in THR use for hip fracture around the world6-8. Data from the 
National Hip Fracture Database (NHFD) show that less than a third of eligible patients undergo THR7. 
There is considerable variation around the UK with the proportion of eligible patients receiving a THR 
ranging from 1 to 60% between individual hospitals7. 
There are clear institutional challenges to widespread provision of THR, including availability of trained 
staff at weekends7. However, use of THR might also be affected by surgeons’ preferences, judgement, 
and interpretation of the research evidence9,10.  
It was in this context that the orthopaedic community eagerly awaited the results of the Hip fracture 
Evaluation with Alternatives of Total Hip arthroplasty versus Hemiarthroplasty (HEALTH) trial11. This 
large and important study was led by a group of well-respected researchers and involved 80 
participating sites across 10 countries. It aimed to compare hemiarthroplasty with THR in the 
population of older adults with hip fracture that were independently mobile before injury. The primary 
outcome was any unplanned secondary hip procedure within 24 months of operation. 
The key findings of the trial were: (a) no significant difference between the groups in terms of 
unplanned secondary procedures at 24 months and (b) a statistically significant functional benefit at 
24-months in favour of THR as measured by the WOMAC total score (mean difference −6.37 (99% CI 
−9.18 to −3.56)). The authors concluded that “the incidence of secondary procedures did not differ 
significantly between patients… and total hip arthroplasty provided a statistically significant but 
clinically unimportant improvement… in function and quality of life over 24 months”. 
The HEALTH trial is a hugely important study so it is worth taking some time to understand the study 
results and how these will influence clinical practice guidelines. 
First, the choice of primary outcome was surprising because the principal advantage of THR is often 
thought to be its perceived functional benefits. Previous work has suggested that the outcomes that 
matter most to hip fracture patients are mortality, pain, activities of daily living, mobility, and health-
related quality of life12. An excess of unplanned procedures would raise concern about an operation 
but more patient-focussed outcome measures were available. Although there was no difference in 
the number of unplanned secondary procedures at 12 or 24 months, there were significantly fewer 
unplanned procedures in the THR group between 12 and 24 months (hazard ratio 0.23 (95% CI 0.08 to 
0.69). Further updates from the HEALTH team will hopefully clarify how time-dependent 
complications specific to hemiarthroplasty (e.g. acetabular erosion) will affect this outcome at later 
timepoints. There were also important differences in the types of unplanned procedures. The most 
frequent secondary procedure in the THR group was closed reduction of hip dislocation (29/57 events) 
and, in the hemiarthroplasty group, implant revision (36/60 events). Although the trial analysed 
unplanned secondary procedures as a binary outcome, there are differences in magnitude of risk 




Second, the authors concluded that the statistically significant functional benefit in favour of THR was 
not clinically important. However, the upper limit of the 99% confidence interval for mean difference 
in EQ-5D utility index score (0.11) was higher than the minimum clinically important difference (MCID) 
that is often accepted for this outcome in the hip fracture population (0.08)13. Similarly, the upper 
limit of the WOMAC score confidence interval reported by HEALTH suggests that the trial may have 
detected a clinically meaningful difference. Importantly, the WOMAC has not been validated in the 
hip fracture population and so the authors relied on a range (9-22) determined from studies of 
patients undergoing THR for hip osteoarthritis. It is therefore possible that the reported mean 
difference of −6.37 (99% CI −9.18 to −3.56) represents a more clinically important functional benefit 
amongst older adults undergoing unscheduled trauma surgery. The functional and HRQoL benefits of 
THR are more likely to become apparent after a number of years14, and so may have been understated 
by the 24-month follow-up data reported by the HEALTH Trial. 
Finally, the HEALTH trial collected WOMAC and EQ5D data at a number of time points: 1 and 10-weeks, 
6, 9, 12, 18 and 24-months. However, these data have not been presented graphically and analysed 
using a longitudinal model for the trend over time and difference in means at each time point, which 
would have aided their interpretation. Analysis of the functional data did not follow an intention-to-
treat analysis and was instead restricted to those with at least one follow-up score. This leaves the 
analysis vulnerable to responder (selection) bias, which is particularly important as the participants 
contributing HRQoL and functional data were notably healthier (younger with fewer co-morbidities) 
than those lost to follow-up. 
The findings of the HEALTH trial are broadly consistent with a recent meta-analysis of five RCTs15-19, 
which also found higher odds of dislocation after THR, higher odds of revision surgery after 
hemiarthroplasty, and mixed evidence supporting a functional benefit after THR. One criticism of RCTs 
is that participants may be carefully selected (limiting generalisability) and receive better treatment 
than the wider patient population (introducing performance bias)20. Importantly, a recent propensity 
score matched study using the NHFD did not find evidence that THR outcomes are worse in the “real 
world” and outside the controlled environment of clinical trials21. These findings can however only be 
generalised to the fittest patients with hip fractures. 
The HEALTH Trial is an important contribution to the literature guiding treatment of displaced 
intracapsular hip fractures in independently mobile patients. The primary outcome measure provides 
very strong support for earlier evidence showing that THR is associated with a higher risk of dislocation 
but a lower risk of other secondary procedures1,2,21. In terms of the more exploratory secondary 
outcomes, the mean difference in functional outcomes demonstrated in the HEALTH trial was smaller 
than those demonstrated in previous studies.  However, the difference still favoured THR and a 
clinically important benefit to patients could not be ruled out. Furthermore, a previous RCT reported 
that such benefits become more obvious after a number of years14. The orthopaedic community look 
forward to further reporting of data from the HEALTH trial participants while recognising that this may 
be difficult to interpret as patients are lost to follow-up over time. In the meantime, we now have 
strong evidence that the rate of unplanned secondary procedures in the first 24 months is similar for 
THR versus hemiarthroplasty. The functional benefits of THR may not be as great as previously 
reported, but it may be premature to update national guidance to exclude THR for selected hip 
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